Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

322.10DKK
3:01am EST
Change (% chg)

kr.1.55 (+0.48%)
Prev Close
kr.320.55
Open
kr.325.95
Day's High
kr.325.95
Day's Low
kr.321.35
Volume
76,381
Avg. Vol
3,122,421
52-wk High
kr.354.80
52-wk Low
kr.230.20

Select another date:

BRIEF-Novo Nordisk Proposes Two New Board Members

* SAYS ‍BOARD OF DIRECTORS PROPOSES ELECTION OF ANDREAS FIBIG AND MARTIN MACKAY AS NEW MEMBERS OF BOARD OF DIRECTORS AT ANNUAL GENERAL MEETING MARCH 22

Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

UPDATE 1-Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON, Feb 22 The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

Novo Nordisk successfully kicks off final-stage trials for first diabetes pill

COPENHAGEN, Feb 22 The world's largest diabetes drugmaker Novo Nordisk on Thursday presented the first successful data from a final-stage study for a pill it hopes will transform the diabetes market.

BRIEF-Novo Nordisk Says Successfully Completes First Trial For Oral Semaglutide

* SUCCESSFULLY COMPLETES THE FIRST PHASE 3A TRIAL, PIONEER 1, WITH ORAL SEMAGLUTIDE

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN, Feb 21 Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

BRIEF-Novo Nordisk Says GLP-1 Drug Ozempic Included In U.S. Express Script 2018 Formulary List

* SAYS ITS GLP-1 DRUG OZEMPIC HAS BEEN INCLUDED IN U.S. EXPRESS SCRIPT 2018 FORMULARY LIST FURTHER COMPANY COVERAGE: (Reporting by Jacob Gronholt-Pedersen)

BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU

* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​

BRIEF-Novo Nordisk Launches Rebinyn In The United States For People With Hemophilia B

* NOVO NORDISK LAUNCHES REBINYN® IN THE UNITED STATES FOR PEOPLE WITH HEMOPHILIA B Source text for Eikon: Further company coverage:

Select another date: